The biological logic behind this strategy begins with a mutation that defines pancreatic cancer. Activating mutations in the KRAS gene occur in roughly ninety percent of pancreatic ductal adenocarcinomas, and the G12D variant, in which glycine at position twelve of the KRAS protein is replaced by aspartic acid, is the most prevalent, accounting for approximately thirty-five to forty percent of cases. KRAS-mutant cancers are famous for rewiring their metabolism, favoring glycolysis even in the presence of oxygen, the phenomenon known as the Warburg effect, while simultaneously ramping up anabolic pathways that convert nutrients into lipids, nucleotides and proteins. Yet this metabolic rewiring creates a paradox: the very enzymes that drive glycolysis also act as bottlenecks, and one of the most important of these checkpoints is the enzyme phosphofructokinase-1, or PFK1, which controls whether glucose-derived carbon flows onward through the glycolytic pathway or is diverted elsewhere.

This is where fructose enters the picture. Unlike glucose, fructose can enter glycolysis downstream of the PFK1 checkpoint. Transported into cells by the fructose-specific transporter GLUT5, encoded by the SLC2A5 gene, fructose is phosphorylated by the enzyme ketohexokinase, or KHK, to form fructose-1-phosphate. The C isoform of this enzyme, KHK-C, then channels fructose-derived carbon into dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, two triose phosphates that sit squarely in the lower half of the glycolytic pathway. In effect, fructolysis allows a cancer cell to bypass one of the body’s principal metabolic control points, feeding carbon directly into the reactions that generate ATP, NADH and, critically, the precursor molecules needed for fatty acid synthesis and the pentose phosphate pathway. The review’s authors argue that KRAS G12D pancreatic cancer cells exploit this bypass with particular enthusiasm, using KHK-C-dependent fructolysis to sustain anabolic growth under the nutrient-poor, oxygen-starved conditions that characterize the pancreatic tumor microenvironment.

The evidence supporting this dependency comes from preclinical studies across multiple pancreatic cancer cell lines, including well-established models such as PANC-1, MIA-PaCa-2, Capan-2, BxPC-3, PSN-1, PaTu-8988T and the aggressive metastatic line L3.6pl. These studies indicate that fructose uptake and phosphorylation can rescue tumor cells when glucose is limiting, a situation that mirrors the glucose-depleted conditions inside real tumors, where dense stromal tissue and chaotic vasculature restrict nutrient delivery. The polyol pathway, which converts glucose to fructose inside the cell through the sequential action of aldose reductases such as AKR1B1 and sorbitol dehydrogenase, adds a second layer of complexity: tumor cells can potentially manufacture their own fructose from glucose, making fructolysis accessible even when dietary fructose is scarce. This endogenous route, the authors note, means that simply avoiding fructose in the diet is unlikely to starve these tumors, and that the enzymes of the polyol pathway, particularly AKR1B1, represent additional druggable targets in the fructose-handling machinery.

Several classes of inhibitors could, in principle, exploit this vulnerability. Blocking GLUT5 would prevent fructose from entering the cell at all. Inhibiting KHK-C would stop fructose from being phosphorylated and funneled into glycolysis. Targeting AKR1B1 would shut down the intracellular conversion of glucose into fructose, cutting off the endogenous supply. Each of these interventions has a defined biochemical rationale, and each has been explored in preclinical models of cancers that consume fructose avidly, including hepatocellular carcinoma and intestinal tumors. In KRAS G12D pancreatic cancer, the review argues, such inhibitors could deprive tumor cells of a critical anabolic lifeline precisely when they are already stressed by glucose scarcity and hypoxia, potentially pushing them past the threshold of metabolic collapse.

But the authors are careful to temper this optimism with a sobering caveat: pancreatic cancer cells are metabolically flexible, and flexibility is the enemy of single-target therapy. When one metabolic pathway is blocked, cancer cells frequently compensate by rewiring others, for example by increasing glutamine consumption through glutaminase 1, by rerouting serine synthesis through phosphoglycerate dehydrogenase, or by shifting their reliance between glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation. The review catalogs this adaptive repertoire in detail, noting enzymes such as pyruvate dehydrogenase kinase 1, which suppresses mitochondrial pyruvate oxidation, the mitochondrial citrate carrier, which exports citrate for lipid synthesis, and the malic enzyme and transaminase routes that shuttle carbon between compartments. Inhibiting fructolysis alone, the authors warn, may simply induce compensatory metabolic rewiring that limits therapeutic efficacy, a pattern that has undermined many previous attempts at single-agent metabolic therapy in oncology.

This is where sodium citrate, a cheap and widely used food additive and pharmaceutical compound, enters the story in a way that few readers would anticipate. The review builds on the authors’ earlier work proposing that high-dose sodium citrate, abbreviated SCT, can act as a broad-acting metabolic inhibitor in cancer cells. Citrate is not merely a passive metabolite: it sits at the junction of glycolysis and the tricarboxylic acid cycle, and its intracellular concentration regulates key enzymes, including PFK1, which citrate inhibits, and ATP citrate lyase, which converts citrate into acetyl-CoA for fatty acid synthesis. By flooding cells with extracellular citrate, sodium citrate can perturb glycolytic flux, interfere with mitochondrial metabolism, and impose widespread metabolic stress. According to the review, experimental pancreatic cancer models harboring not only KRAS G12D but also KRAS G12C, KRAS G12V and even KRAS wild-type backgrounds respond to SCT with reduced growth, suggesting that its antitumor activity is not confined to the fructolysis-dependent G12D subset but may extend across the molecular diversity of pancreatic cancer.

The proposed combination is therefore a one-two punch: a specific fructolysis inhibitor, such as a KHK or GLUT5 blocker, delivers a targeted blow to the fructose bypass, while sodium citrate applies broader pressure on glycolytic and mitochondrial metabolism, making it harder for tumor cells to compensate through alternative routes. The authors also highlight evidence that sodium citrate may enhance the sensitivity of tumor cells to commonly used pancreatic cancer chemotherapeutics, including agents such as 5-fluorouracil, and may potentiate cytotoxic immune responses, potentially involving CD8-positive T cells and other components of the antitumor immune repertoire. If these effects hold up in rigorous testing, the combination could address two chronic weaknesses of metabolic therapy at once: incomplete pathway blockade and immune evasion.

It is essential to emphasize what this review does and does not claim. This is a synthesis of preclinical evidence and mechanistic reasoning, not the report of a completed clinical trial. No patient data demonstrate that fructolysis inhibitors or high-dose sodium citrate improve survival in pancreatic cancer, and the doses of sodium citrate discussed in experimental models far exceed ordinary dietary exposure. The authors themselves frame their conclusions as hypotheses that warrant investigation, and they explicitly suggest that the therapeutic potential of sodium citrate should be explored independently of the KRAS G12D fructolytic dependency, given its activity across multiple KRAS backgrounds. Translating these ideas into the clinic will require pharmacokinetic studies, safety assessments, carefully designed combination regimens and, ultimately, randomized trials in patients whose tumors have been molecularly characterized for KRAS mutation status and metabolic phenotype.

Nevertheless, the conceptual contribution is significant. Pancreatic ductal adenocarcinoma remains one of the few major cancers whose five-year survival has barely improved over decades, and the field urgently needs targets that exploit the specific metabolic dependencies of KRAS-mutant cells. The idea that a dietary sugar’s metabolic pathway, operating through GLUT5, KHK-C and the polyol pathway, could constitute an actionable vulnerability reframes fructose from a nutritional afterthought into a central player in tumor biochemistry. Whether the combination of fructolysis inhibition with sodium citrate can survive the gauntlet of clinical validation remains an open question, but the review provides a detailed mechanistic roadmap for testing it, and in doing so adds a provocative new chapter to the ongoing effort to outmaneuver one of medicine’s most stubborn cancers.

Subject of Research: Fructose metabolism as a therapeutic vulnerability in KRAS G12D pancreatic ductal adenocarcinoma

Article Title: Fructose metabolism in pancreatic ductal adenocarcinoma: emerging vulnerabilities in KRAS G12D tumors and therapeutic perspectives with sodium citrate

Article References: Fructose metabolism in pancreatic ductal adenocarcinoma: emerging vulnerabilities in KRAS G12D tumors and therapeutic perspectives with sodium citrate. (n.d.). https://doi.org/10.1186/s13046-026-03829-w

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03829-w

Keywords: pancreatic cancer, KRAS G12D, fructolysis, ketohexokinase, sodium citrate, cancer metabolism, Warburg effect, polyol pathway, GLUT5, targeted therapy, PDAC, metabolic vulnerability